BioSpace News Archive

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, Sept. 13, 2023 at 10:30 a.m. ET.

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis, announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber for the knee.

Endeavor BioMedicines today announced that the company has completed enrollment in its Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 (taladegib) for the treatment of idiopathic pulmonary fibrosis (IPF). ENV-101 is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in IPF disease pathology.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on Monday, September 11, 2023.

Ventus Therapeutics announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 AM ET.

Halberd Corporation’s research at Mississippi State University has shown significant reduction in two key markers of traumatic brain injury in early testing of Halberd’s patent-pending nasal spray to mitigate the effects of TBI.

Teva to Present Data for AUSTEDO ® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO ® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023.

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities.

CorMedix Inc. today announced that management will be giving a company presentation at the H.C. Wainwright Global Investment Conference being held in New York City on September 11 – 13, 2023.

Inozyme Pharma, Inc. today announced that it granted stock options to a new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan.